8-K: Travere Therapeutics Q2 2025: FILSPARI Sales Soar

Travere Therapeutics reported strong second quarter 2025 financial results, driven by a 165% year-over-year growth in U.S. net product sales of FILSPARI, alongside significant regulatory and clinical advancements.

Summary

• U.S. net product sales of FILSPARI (sparsentan) grew 165% year-over-year to $71.9 million in the second quarter of 2025.
• Total revenue for Q2 2025 was $114.4 million, including $94.8 million in net product sales and a $17.5 million milestone payment from CSL Vifor.
• The company received 745 new patient start forms (PSFs) for FILSPARI in Q2 2025, indicating continued uptake.
• Net loss for Q2 2025 significantly decreased to $12.8 million, or $0.14 per basic share, compared to a net loss of $70.4 million, or $0.91 per basic share, in Q2 2024.
• The FDA accepted the supplemental new drug application (sNDA) for FILSPARI in FSGS, setting a PDUFA target action date of January 13, 2026, and planning an advisory committee meeting.
• The European Commission and UK Medicines and Healthcare products Regulatory Agency converted conditional marketing authorization of FILSPARI to standard approval for IgAN.
• Research and development (R&D) expenses decreased to $49.4 million in Q2 2025 from $54.3 million in Q2 2024, primarily due to lower costs for pegtibatinase and sparsentan trials.
• Selling, general, and administrative (SG&A) expenses increased to $76.2 million in Q2 2025 from $64.8 million in Q2 2024, driven by increased investment in FILSPARI commercialization and preparation for a potential FSGS launch.
• Cash, cash equivalents, and marketable securities totaled approximately $319.5 million as of June 30, 2025.
• The company remains on track to restart enrollment in the Phase 3 HARMONY Study for pegtibatinase in classical HCU in 2026.

Sentiment

Score: 8

Explanation: The filing indicates strong positive momentum with significant revenue growth, a substantial reduction in net loss, and key regulatory and clinical advancements for its lead product, FILSPARI. The progress on pipeline assets also adds to the positive outlook, despite continued net losses and increased SG&A.

Positives

• U.S. net product sales of FILSPARI grew 165% year-over-year to $71.9 million in Q2 2025, demonstrating strong commercial momentum.
• Total revenue for Q2 2025 reached $114.4 million, a substantial increase from $54.1 million in Q2 2024.
• A $17.5 million milestone payment was received from CSL Vifor following the conversion of FILSPARI's conditional marketing authorization to standard approval in the EU and UK for IgAN.
• Net loss significantly reduced to $12.8 million in Q2 2025 from $70.4 million in Q2 2024, indicating improved financial efficiency.
• The FDA accepted the sNDA for FILSPARI in FSGS, with a PDUFA target action date of January 13, 2026, potentially making it the first FDA-approved treatment for FSGS.
• Positive new data on FILSPARI's use in IgAN were presented at major conferences, showing rapid and sustained reductions in albuminuria and proteinuria, stable eGFR, and disease-modifying activity.
• The SPARTAN Study is expanding to include post-kidney transplant patients with recurring IgAN, and a new open-label study for post-kidney transplant IgAN or FSGS is initiating, broadening FILSPARI's potential application.
• The company is on track to restart enrollment in the Phase 3 HARMONY Study for pegtibatinase in classical HCU in 2026, advancing a potential first disease-modifying therapy.

Negatives

• Despite significant improvement, the company still reported a net loss of $12.8 million for the second quarter of 2025.
• Selling, general, and administrative (SG&A) expenses increased by $11.4 million year-over-year to $76.2 million, driven by commercialization and launch preparation investments.

Risks

• There is no guarantee that the FDA will grant full approval of FILSPARI for FSGS on the anticipated timeline or at all.
• The success of commercial products, including market acceptance, efficacy, safety, price, reimbursement, and benefit over competing therapies, is uncertain.
• Risks and uncertainties are associated with the company's preclinical and clinical stage pipeline, including the possibility that ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory, or other reasons.
• Challenges exist with manufacturing scale-up for commercial products.
• The company faces risks related to its dependence on contractors for clinical drug supply and commercial manufacturing.
• Uncertainties exist regarding patent protection, exclusivity periods, and intellectual property rights of third parties.
• The company may be unable to raise additional funding that may be required to complete development of any or all of its product candidates, potentially exacerbated by macroeconomic conditions.
• FILSPARI carries a BOXED WARNING for hepatotoxicity and embryo-fetal toxicity, requiring a restricted program (FILSPARI REMS) with mandatory monitoring and contraception.
• Elevations in aminotransferases (ALT or AST) have been observed in up to 3.5% of FILSPARI-treated patients, necessitating regular liver function monitoring.
• FILSPARI is contraindicated in pregnant patients and can cause major birth defects if used during pregnancy.
• Potential adverse reactions include hypotension, acute kidney injury, hyperkalemia, and fluid retention.
• Concomitant use of FILSPARI with certain drugs (e.g., ARBs, ERAs, strong CYP3A inhibitors, antacids, NSAIDs) can lead to increased risks or reduced efficacy.

Future Outlook

The company anticipates FILSPARI becoming a foundational treatment for IgAN and potentially the first FDA-approved therapy for FSGS, with a PDUFA target action date of January 13, 2026. A PDUFA action date of August 28, 2025, is expected for REMS modification, which could support broader access to FILSPARI. Enrollment in the pivotal study of pegtibatinase for classical HCU is on track to restart in 2026. The final version of the updated KDIGO clinical guidelines for IgAN is expected in the second half of 2025, and topline results from Renalys Pharma's Phase 3 IgAN trial in Japan are also anticipated in the second half of 2025. The company remains eligible for additional milestone payments related to market access and sales-based achievements.

Management Comments

• "We continue to make strong progress against our strategic priorities, putting Travere on a trajectory for both nearand long-term growth."
• "This quarter marked our strongest commercial performance to date, with increased momentum for FILSPARI resulting in significant growth in a dynamic IgAN market."
• "Looking ahead, we are well positioned to continue advancing FILSPARI toward becoming a foundational treatment."
• "In parallel, we are preparing for a potential approval in FSGS, where FILSPARI would become the first FDA-approved therapy bringing a long-awaited option to patients and further extending our impact in rare kidney diseases."
• "We also look forward to our upcoming August PDUFA date for REMS modification, which could result in important label updates that support broader access to FILSPARI."
• "Additionally, we are making steady progress toward restarting enrollment in our pivotal study of pegtibatinase, moving us closer to potentially delivering the first disease-modifying therapy for people living with classical HCU."

Industry Context

This announcement positions Travere Therapeutics as a growing player in the rare kidney disease space, particularly within IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). FILSPARI's strong sales growth and progress towards standard marketing authorization in Europe and the UK, along with the FDA's acceptance of the sNDA for FSGS, indicate increasing market penetration and potential expansion into new indications. The ongoing clinical studies and the anticipated KDIGO guideline updates suggest a dynamic treatment landscape where FILSPARI aims to become a foundational therapy, potentially offering the first FDA-approved treatment for FSGS, a significant unmet medical need. The progress with pegtibatinase also highlights the company's commitment to addressing other rare metabolic kidney disorders like classical HCU.

Comparison to Industry Standards

• In the Phase 2 SPARTACUS Study, FILSPARI demonstrated superior efficacy compared to maximally tolerated RASi, achieving rapid and sustained albuminuria (~56% from baseline) and proteinuria (~45% from baseline) reductions, with stable eGFR.
• In the Phase 3 DUPLEX Study, FILSPARI showed earlier and more frequent partial and complete proteinuria remission compared to irbesartan, validating its nephroprotective potential.
• The company's 165% year-over-year growth in U.S. net product sales of FILSPARI for IgAN indicates strong market adoption relative to new rare disease drug launches.

Stakeholder Impact

• Shareholders: Positive financial results, strong product growth, and pipeline advancements could lead to increased shareholder value and confidence.
• Patients: Potential for FILSPARI to become a foundational treatment for IgAN and the first FDA-approved therapy for FSGS offers new, long-awaited treatment options for rare kidney diseases. REMS modification could improve access.
• Prescribers: New clinical data and potential label updates for FILSPARI could support broader adoption and provide more clarity on its use.
• Employees: Continued company growth and pipeline progress may lead to job stability and potential expansion opportunities.
• Partners (CSL Vifor, Renalys Pharma): Achievement of milestones and progress in clinical trials strengthen partnerships and potential for future collaborations and revenue sharing.

Next Steps

• Anticipated PDUFA action date of August 28, 2025, for the sNDA to remove embryo-fetal toxicity REMS monitoring and modify liver monitoring frequency for FILSPARI.
• Anticipated publication of the final version of the updated Kidney Disease Improving Global Outcomes (KDIGO) clinical guidelines for IgAN in the second half of 2025.
• Renalys Pharma, Inc. expects topline results from its registrational Phase 3 clinical trial of sparsentan for IgAN in Japan in the second half of 2025.
• FDA PDUFA target action date of January 13, 2026, for the sNDA for FILSPARI in FSGS, with an advisory committee meeting planned.
• Restart enrollment in the Phase 3 HARMONY Study for pegtibatinase in classical HCU in 2026.
• Initiate a new open label study of FILSPARI in post-kidney transplant patients with recurrent IgAN or FSGS.

Key Dates

Recommendation

The filing demonstrates exceptional commercial performance for FILSPARI, with 165% year-over-year sales growth, and a significant reduction in net loss, indicating improving financial health. Key regulatory milestones, such as the FDA's acceptance of the FSGS sNDA with a PDUFA date and the conversion to standard marketing authorization in Europe/UK, de-risk future revenue streams and expand market potential. The positive clinical data presented reinforces FILSPARI's efficacy and disease-modifying potential. Furthermore, the progress with pegtibatinase adds another promising asset to the pipeline. These factors collectively suggest strong near-term catalysts and long-term growth prospects, making it an attractive investment.

Keywords

Travere Therapeutics, TVTX, FILSPARI, sparsentan, IgAN, FSGS, rare kidney disease, pegtibatinase, classical HCU, biopharmaceutical, Q2 2025, financial results, SEC filing, drug approval, clinical trials